Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: sodium chloride; histidine; borax; aluminium; water for injections; polysorbate 80 - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium -

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - desogestrel; ethinylestradiol - tablets - desogestrel 150 mcg; ethinylestradiol 30 mcg - desogestrel and estrogen - desogestrel and estrogen - oral contraceptive.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - bacillus calmette-guerin substrain tice live antigen (unii: 2xq558l16z) (bacillus calmette-guerin substrain tice live antigen - unii:2xq558l16z) - bacillus calmette-guerin substrain tice live antigen 50 mg - bcg vaccine (tice® strain) is indicated for the prevention of tuberculosis in persons not previously infected with m. tuberculosis who are at high risk for exposure. as with any vaccine, immunization with bcg vaccine may not protect 100% of susceptible individuals. the advisory committee on immunization practices (acip) and the advisory committee for the elimination of tuberculosis has recommended that bcg vaccination be considered in the following circumstances.{3} bcg vaccination is recommended for infants and children with negative tuberculin skin tests who are (a) at high risk of intimate and prolonged exposure to persistently untreated or ineffectively treated patients with infectious pulmonary tuberculosis and who cannot be removed from the source of exposure and cannot be placed on long-term primary preventive therapy, or (b) continuously exposed to persons with infectious pulmonary tuberculosis who have bacilli resistant to isoniazid and rifampin, and the child cannot be separated from the presence of the infectious patient.{3} bcg vaccination of hcws should be considered on an individual basis in settings where (a) a high percentage of tb patients are infected with m. tuberculosis strains resistant to both isoniazid and rifampin, (b) transmission of such drug resistant m. tuberculosis strains to hcws and subsequent infection are likely, and (c) comprehensive tb infection control precautions have been implemented and have not been successful. vaccination should not be required for employment or for assignment of hcws in specific work areas. hcws considered for bcg vaccination should be counseled regarding the risks and benefits associated with both bcg vaccinations and tb preventive therapy.{3} bcg vaccination is not recommended for hcws in settings in which the risk for m. tuberculosis transmission is low.{3} bcg vaccine for prevention of tuberculosis should not be given to persons (a) whose immunologic responses are impaired because of hiv infections, congenital immunodeficiency such as chronic granulomatous disease or interferon gamma receptor deficiency, leukemia, lymphoma, or generalized malignancy or (b) whose immunologic responses have been suppressed by steroids, alkylating agents, antimetabolites, or radiation.{3} bcg vaccine should not be administered to hiv-infected or immunocompromised infants, children, or adults. prior to administration, the possibility of allergic reactions should be assessed. allergy to any component of bcg vaccine or an anaphylactic or allergic reaction to a previous dose of bcg vaccine are contraindications for vaccination. bcg vaccine is not a vaccine for the treatment of active tuberculosis. bcg vaccine should not be used in infants, children, or adults with severe immune deficiency syndromes. children with a family history of immune deficiency disease should not be vaccinated; if they are, an infectious disease specialist should be consulted and anti-tuberculous therapy administered if clinically indicated.{18} please read this leaflet carefully before administering bcg vaccine. the vaccine is to be administered after fully explaining the risks and benefits to the vaccinee, parent, or guardian. bcg vaccination should not be given to individuals previously infected with m. tuberculosis. the sterile, single-use multiple puncture device is for use with the bcg vaccine only. figure 1 figure 2 figure 5 caution: federal law restricts this device to sale by or on the order of a physician. multiple puncture devices may be obtained separately from the order management center, merck sharp & dohme llc, 351 north sumneytown pike, north wales, pa 19454-2505, telephone number: 800-637-2579.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide -